Ivan Kopljar,
Post Doctorial Research Scientist,
The Janssen Pharmaceutical Companies of Johnson & Johnson
Dr. Ivan Kopljar is a post doc scientist in the department of Global Safety Pharmacology at Janssen Pharmaceutica (J&J). His research focusses on the application of human stem cell-derived cardiomyocytes in drug safety. Currently, he is involved in the development of high throughput screening assays and investigation of drug-induced chronic cardiotoxicity using human stem cell-derived cardiomyocytes. Dr. Kopljar received his Ph.D. in Biochemistry from the University of Antwerp.
|
|
|
Add to Calendar ▼2017-03-07 16:30:002017-03-07 17:30:00Europe/LondonhiPS Cardiomyocytes in Drug Safety: Ca2+ Assay Optimization and Experimental Variability SELECTBIOenquiries@selectbiosciences.com
.gif){kind=logo}
